Answers are grounded in this paper and cite their sources.
Given its rarity, drug-related hepatotoxicity may not be seen during the initial clinical trials of a new medication. After approval, when many more patients are exposed, toxic effects that are very infrequent may emerge. This review explains the difficulties in identifying the cause of hepatotoxic effects in such situations and provides clinical guidance with regard to the detection, evaluation, and possible prevention of drug-related hepatotoxicity.
No takes yet. Share an insight, caveat, or question.
Navarro et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: